Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipicolinic Acid SCHEMBL3974348 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL3974346 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL3059430 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL7699646 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL9753719 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL2276246 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL9491857 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL3972222 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL3340788 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL795787 | 0.95 | KDM4E (0.56) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148748-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | NUTRITION21 LLC (US) | 2024-05-09 | — | — | US | disclosed |
| US-11865121-B2 | Chromium containing compositions for improving health and fitness | Nutrition21, LLC (US) | 2024-01-09 | — | — | US | disclosed |
| US-11857553-B2 | Chromium containing compositions for improving health and fitness | Nutrition21, LLC (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3050568-B1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | JDS THERAPEUTICS LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20190314510-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190216821-A1 | Chromium Containing Compositions for Improving Health and Fitness | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10245325-B2 | Methods and compositions for the sustained release of chromium | JDS THERAPEUTICS, LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3413900-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | Nutrition 21, LLC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20170304360-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2017-10-26 | — | — | US | disclosed |
| US-20170239267-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2017-08-24 | — | — | US | disclosed |
| EP-3050568-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | Nutrition 21, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2134351-B1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | NUTRITION 21 INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20150320874-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320796-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-11-12 | — | — | US | disclosed |
| US-9119835-B2 | Methods and compositions for the sustained release of chromium | JDS Therapeautics, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120128794-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | NUTRITION 21, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8062677-B2 | Methods and compositions for the sustained release of chromium | NUTRITION 21, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2134351-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | Nutrition 21, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090155384-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2009-06-18 | — | — | US | disclosed |
| WO-2008112706-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | NUTRITION 21, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155384-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
| US-20120128794-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
| US-20150320874-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
| US-20190216821-A1 | Chromium Containing Compositions for Improving Health and Fitness | GYS1, MUSK, PYGM | KDM4E 3543/4885ALOX15 3835/4885TSHR 559/4885 |
| US-20240148748-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | GYS1, MUSK, PYGM | KDM4E 3543/4885ALOX15 3835/4885TSHR 559/4885 |
| US-20190314510-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
| US-11865121-B2 | Chromium containing compositions for improving health and fitness | GYS1, MUSK, PYGM | KDM4E 3543/4885ALOX15 3835/4885TSHR 559/4885 |
| US-10245325-B2 | Methods and compositions for the sustained release of chromium | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
| US-20170239267-A1 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | GYS1, MUSK, PYGM | KDM4E 3543/4885ALOX15 3835/4885TSHR 559/4885 |
| US-20170304360-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
| US-11857553-B2 | Chromium containing compositions for improving health and fitness | GYS1, MUSK, PYGM | KDM4E 3543/4885ALOX15 3835/4885TSHR 559/4885 |
| US-20150320796-A1 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | LDLR, TNNC1, LIPA | KDM4E 3111/4885ALOX15 726/4885TSHR 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.